Partnerships & Investors

Together we can unlock the power of the immune network

Transimmune maintains close collaborations with leading academic centers in Europe and the United States that include specialized clinical institutions, translational and research centers of excellence. These provide us with the ability to access rapid prototyping, disease model systems and clinical expertise.

Partnership & Investors
Circle Illustration


Yale University

We have collaborated intensively for many years with researchers in Dr. Edelson’s lab in the Department of Dermatology at Yale School of Medicine. Dr Edelson and colleagues were the pioneers of extracorporeal photopheresis and continue to uncover insights into the central role of platelet-activated dendritic cells and how to broaden their usage into new disease indications. Yale are a valued research partner in Transimmune's work with the Bill & Melinda Gates Foundation and under the ARPA-H grant.

EMORY University

Dr. Santangelo’s lab at Emory University are world leaders in the research of mRNA vaccines and therapeutics, particularly in the field of infectious diseases. Emory are a valued research partner in Transimmune’s work with the Bill & Melinda Gates Foundation and under the ARPA-H grant.



QureInvest is an entrepreneurial investment fund managed by HS LifeSciences, committed to invest in early-stage companies within the medical innovation sector.
Circle Illustration

Partnering Contact

Justin Duckworth Circle Illustration
Justin Duckworth
Mr Duckworth is a founder of Transimmune and became CEO in 2022. Prior to that he was a healthcare venture capitalist of 22 years, most recently as Managing General Partner of QureInvest Fund. In addition to fund management, he was heavily involved in corporate development for portfolio companies Ethris and Transimmune. Prior to QureInvest, he was a Partner at Nomura Phase4 Ventures and an advisor at HBM Partners. He studied biochemistry at the Oxford University and is an ACA.